Decoy Therapeutics Inc., formerly known as Salarius Pharmaceuticals, reported significant financial developments in its recent 10-K filing for the fiscal year ending December 31, 2025. The company, which focuses on developing peptide conjugate therapeutics through its proprietary IMP3ACT platform, recorded a net loss of $12.5 million, a substantial increase from a loss of $5.6 million in the previous year. This increase is primarily attributed to $8.5 million in acquired in-process research and development expenses related to its merger with Legacy Decoy, which was finalized on November 12, 2025.
The company’s total operating expenses for 2025 reached $12.6 million, compared to $5.7 million in 2024, reflecting a significant rise in research and development costs. General and administrative expenses decreased to $3.7 million from $5.0 million, largely due to reduced personnel costs and public company expenses. As of December 31, 2025, Decoy had cash and cash equivalents totaling $10.7 million, which includes approximately $3.0 million restricted under a grant agreement with the Gates Foundation. The company anticipates that its current cash reserves will sustain operations into late 2026, but it will require additional capital to continue its development activities.
Strategically, Decoy has made notable advancements, including the completion of a reverse stock split on March 6, 2026, which was part of its compliance plan to meet Nasdaq's minimum bid price requirement. Following the split, the company achieved a closing bid price of $7.47, thereby regaining compliance with Nasdaq listing standards. The merger with Legacy Decoy has expanded Decoy's pipeline to include not only peptide conjugate candidates but also small molecule drugs targeting gene dysregulation, such as SP-3164 and SP-2577, the latter of which has received FDA fast track designation.
Operationally, Decoy is in the preclinical stage and has not yet generated revenue from product sales. The company is focused on advancing its lead programs, particularly a pan-Coronavirus prophylactic aimed at immunocompromised patients, with plans to file an Investigational New Drug (IND) application in the first half of 2027. The company’s future success hinges on its ability to navigate the complexities of drug development, secure additional funding, and effectively manage its research and development activities. The filing also highlights the risks associated with its business model, including reliance on third-party collaborations and the challenges of maintaining compliance with regulatory requirements.
About Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies, including protein degraders and inhibitors. Its pipeline features drugs like SP-3164 and SP-2577, aimed at high unmet need cancers such as hematological malignancies and pediatric sarcomas. The company collaborates with academic institutions, holds key patents, and advances through regulatory pathways to bring innovative treatments to oncology markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.